BioNTech (NASDAQ:BNTX – Get Rating) received a $312.00 target price from stock analysts at Berenberg Bank in a research report issued on Tuesday, Borsen Zeitung reports. Berenberg Bank’s price target suggests a potential upside of 94.55% from the stock’s current price.
Other equities research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft set a $180.00 price target on BioNTech in a research note on Thursday, September 8th. HC Wainwright decreased their target price on BioNTech from $283.00 to $272.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th. Cowen started coverage on BioNTech in a report on Wednesday, August 17th. They issued a “market perform” rating for the company. Morgan Stanley increased their price target on BioNTech from $194.00 to $203.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. dropped their price target on BioNTech from $183.00 to $132.00 and set a “neutral” rating on the stock in a research report on Monday, October 24th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $215.92.
BioNTech Trading Down 0.2 %
BioNTech stock traded down $0.35 during trading on Tuesday, hitting $160.37. The company’s stock had a trading volume of 27,627 shares, compared to its average volume of 894,595. The stock has a market capitalization of $38.92 billion, a price-to-earnings ratio of 3.10 and a beta of 0.12. The stock’s fifty day moving average is $138.51 and its 200 day moving average is $148.29. BioNTech has a 1-year low of $117.08 and a 1-year high of $374.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.15.
BioNTech (NASDAQ:BNTX – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported $6.98 EPS for the quarter, topping the consensus estimate of $3.42 by $3.56. The company had revenue of $3.46 billion during the quarter, compared to analyst estimates of $1.90 billion. BioNTech had a return on equity of 88.76% and a net margin of 55.43%. The firm’s revenue was down 43.1% on a year-over-year basis. During the same period in the prior year, the firm posted $14.56 earnings per share. As a group, equities research analysts predict that BioNTech will post 32.49 EPS for the current year.
Hedge Funds Weigh In On BioNTech
Several institutional investors have recently bought and sold shares of BNTX. International Biotechnology Trust PLC bought a new position in shares of BioNTech in the second quarter valued at approximately $26,000. Eagle Bay Advisors LLC acquired a new position in shares of BioNTech in the 2nd quarter valued at $33,000. Huntington National Bank acquired a new position in BioNTech in the 3rd quarter worth $34,000. Heritage Wealth Management LLC acquired a new position in BioNTech in the 2nd quarter worth $36,000. Finally, Activest Wealth Management boosted its stake in BioNTech by 39,000.0% in the 3rd quarter. Activest Wealth Management now owns 391 shares of the company’s stock worth $53,000 after purchasing an additional 390 shares during the period. 13.77% of the stock is currently owned by institutional investors.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.